Loading stock data…
AXSM
$223.06-0.28 (-0.13%)
Pre-Market$222.75-0.31 (-0.14%)· Last close May 5
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axsome Therapeutics, Inc. in the Healthcare sector is trading at $223.06. The stock is currently near its 52-week high of $234.29, remaining 50.0% above its 200-day moving average. Technical signals show overbought RSI of 78 and bullish MACD crossover, explaining why AXSM maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 78) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$223.06
Potential Upside
5%
Whystock Fair Value$234.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Mean target$235.85+5.7%
Range$198.82 – $281.00
Fundamentals
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextrometho...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-279.63%
Volume
Today's trading volume
814,368
Recent News
3 Overlooked Stocks Set to Soar in 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Axsome Continues Its Breakneck Pace On Solid First-Quarter Sales
Axsome stock jumped Monday on in-line first-quarter sales following FDA approval of Auvelity in Alzheimer's agitation on Friday.
Why This Biotech ETF — The IBD Stock Of The Day — Just Reentered Its Buy Zone
The SPDR S&P Biotech ETF, often referred to simply as the XBI, is Monday's IBD Stock Of The Day. Shares just reentered a buy zone.
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
Investors think a new addition to the biotech's pipeline could be the next catalyst.
Axsome Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Axsome Therapeutics, Inc.'s Q1 2026 earnings call